一个新的机器人超声波系统在透析过程中在成像肾病患者方面取得了很高的成功,有可能改善血管接触结果。 A new robotic ultrasound system achieved high success in imaging kidney patients during dialysis, potentially improving vascular access outcomes.

由澳大利亚公司Vexev开发并与美国Renal Care合作测试的VxWave超声波成像系统成功满足了CANSCAN试验中的所有临床端点,这是该试验的首次实物研究,涉及115名肾病晚期患者。 The VxWave Ultrasound Imaging System, developed by Australian company Vexev and tested in collaboration with U.S. Renal Care, successfully met all clinical endpoints in the CANSCAN Trial, a first-of-its-kind study involving 115 patients with advanced kidney disease. 机器人系统实现了94%的扫描完成率和100%的数据充足率,独立血管专家对图像的评分足够。 The robotic system achieved a 94% scan completion rate and 100% data adequacy, with images rated sufficient by independent vascular specialists. 该系统设计为半自主、透析访问时按需使用,旨在克服长期存在的挑战,如患者不合规、扫描质量不一致以及血管访问图绘制费用高昂。 Designed for semi-autonomous, on-demand use during dialysis visits, the system aims to overcome longstanding challenges like poor patient compliance, inconsistent scan quality, and high costs in vascular access mapping. 在2025年基德尼周上介绍的成果表明,该技术可以通过实现标准化和精确的成像来提高动脉瘘和移植术的成功率,从而改进成果。 Results presented at Kidney Week 2025 suggest the technology could improve outcomes by enabling standardized, precise imaging to increase the success of arteriovenous fistulas and grafts.